The Neuropathology Core is an essential part of the Alzheimer's Disease Core Center (ADCC). During life, the signs and symptoms of Alzheimer's disease (AD) are not sufficiently different from several other conditions, resulting in misdiagnosis, even at the most advanced centers, in about 25% of subjects. Examination of the brain after death by a certified Neuropathologist is therefore the only means by which a definite diagnosis can be attained, allowing all research results to be correctly interpreted. A second major role of the Neuropathology Core is to provide neuropathologically characterized brain tissue to basic scientists, both within the ADCC and outside it, enabling them to discover the underlying molecular mechanisms of disease and design appropriate therapeutic interventions. A detailed understanding of the genetic and molecular processes of disease pathogenesis, obtained by comparative study of diseased and non-diseased brain tissue, remains the major approach to finding such interventions. A third important goal of the Neuropathology Core is to help develop a collaborative synergy that will enhance the research productivity of the entire Center.
Our Specific Aims are as follows: 1)To provide precise neuropathoiogic diagnoses of patients that have been clinically studied by the Cinical Core. 2) To provide basic scientists with neuropathologically characterized brain tissue suitable for the elucidation of the molecular mechanisms of AD and related disorders, and especially to assist researchers in their studies of the earliest stages of Alzheimer's disease, with the goal of identifying therapeutic strategies that will prevent the disease or slow its progress. 3) To share neuropathological skills, expertise, knowledge and data with all ADCC investigators and the scientific community at large, facilitating a collaborative synergy that will enhance the research productivity of all.

Public Health Relevance

The Arizona Alzheimer's Disease Center's Neuropathology Core provides autopsy services, brain measurements and diagnoses, and brain and body samples from research participants in the Clinical Core who have died and donated their brains (and sometimes their bodies) to advance the scientific understanding, treatment and prevention of Alzheimer's disease. It works closely with the other Cores and plays a critical role in the scientific fight against Alzheimer's Disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG019610-15
Application #
8805818
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Banner Health
Department
Type
DUNS #
City
Phoenix
State
AZ
Country
United States
Zip Code
85351
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Quiroz, Yakeel T; Sperling, Reisa A; Norton, Daniel J et al. (2018) Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurol 75:548-556
Chen, Hsu-Hsin; Liu, Peter; Auger, Paul et al. (2018) Calpain-mediated tau fragmentation is altered in Alzheimer's disease progression. Sci Rep 8:16725
Klimentidis, Yann C; Raichlen, David A; Bea, Jennifer et al. (2018) Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. Int J Obes (Lond) 42:1161-1176
Tu, Yanshuai; Wen, Chengfeng; Zhang, Wen et al. (2018) Isometry Invariant Shape Descriptors for Abnormality Detection on Brain Surfaces Affected by Alzheimer's Disease. Conf Proc IEEE Eng Med Biol Soc 2018:427-4631
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Caneus, Julbert; Granic, Antoneta; Rademakers, Rosa et al. (2018) Mitotic defects lead to neuronal aneuploidy and apoptosis in frontotemporal lobar degeneration caused by MAPT mutations. Mol Biol Cell 29:575-586
Caselli, Richard J; Langlais, Blake T; Dueck, Amylou C et al. (2018) Personality Changes During the Transition from Cognitive Health to Mild Cognitive Impairment. J Am Geriatr Soc 66:671-678
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558

Showing the most recent 10 out of 794 publications